INTRODUCTION
Induction therapy with conventional chemotherapy agents in myeloma generally produced an overall response rate (ORR) of 50% to 60%. 1 The landscape of myeloma therapy changed with the introduction of novel agents, eg, proteasome inhibitors (PIs) and immunomodulatory agents (IMiDs), which can yield a response in 80% to 90% of patients. 2 The response rates are even more impressive with the new generation of PIs and IMiDs, in which ORRs can exceed 90%. 2 However, the prognostic value of the depth of response to induction therapy in patients who proceed to autologous hematopoietic stem cell transplantation (auto-HCT) is a topic of discussion. Before the introduction of novel agents, the depth of response in patients responding to conventional agents before auto-HCT was not clearly associated with longer survival. [3] [4] [5] However, more recent data with novel agents suggest that depth of response to induction therapy correlates with superior progression-free survival (PFS) 6 and overall survival (OS) after auto-HCT. 7 Conversely, patients who have disease that is refractory to induction therapy with either conventional therapy or novel agents have poorer outcomes after auto-HCT versus responding patients. 3, 4, [8] [9] [10] [11] The patients with myeloma who fail to respond to induction therapy (primary refractory) or become refractory after an initial response (relapsed and refractory) have dismal outcomes. Many of these patients become refractory to both PIs and IMiDs (double-refractory). These constitute a higher risk population for which there are scant data on the role of auto-HCT. 8, 12, 13 To characterize the role of auto-HCT in patients with refractory multiple myeloma (MM), particularly those with double-refractory disease, we assessed the outcomes of patients who underwent auto-HCT at our center and had a response status of less than a partial response (PR) at the time of transplantation.
MATERIALS AND METHODS

Patients
We retrospectively identified all patients with relapsed and refractory myeloma (defined as disease that was nonresponsive while patients were receiving salvage therapy or progression within 60 days of therapy in those who had achieved a minimal response or better) and primary refractory myeloma (defined as disease that was nonresponsive in patients who never achieved a minimal response or better with any therapy) 14 who underwent first auto-HCT at The University of Texas MD Anderson Cancer Center between March 2000 and October 2015. A patient was deemed nonresponsive if they achieved less than a PR (ie, stable disease or progressive disease) to the therapy received. The number of cycles received before the patient was considered unresponsive to a particular regimen was at the discretion of the primary oncologist. The study population was divided into 2 groups: 1) patients with double-refractory MM (DR-MM) (ie, those who were refractory to at least 1 IMiD and at least 1 PI 12 , and 2) patients with nondouble-refractory MM (NDR-MM) (ie, those with refractory disease not classified as DR-MM). The Institutional Review Board at MD Anderson Cancer Center approved this study.
Clinical and Outcome Measures
Cytogenetic risk was assessed based on cytogenetic analysis and interphase fluorescence in situ hybridization (FISH) analysis results. Patients were defined as having high-risk MM if conventional cytogenetics in at least 2 metaphases performed at diagnosis or at any time before auto-HCT demonstrated t(4;14), t(14;16), t (14;20) , 213/del(13q), 217/del(17p), hypodiploidy (<45 chromosomes excluding 2Y), or a chromosome 1 aberration (11, 21, The time to neutrophil engraftment was the first of 3 consecutive days with an absolute neutrophil count 0.5 3 10 9 /L after post-transplantation nadir. 15 Platelet engraftment was defined as the first of 7 consecutive days with a platelet count of 20 3 10 9 /L in the absence of platelet transfusion for the preceding 7 days. 15 International Myeloma Working Group criteria were used to define treatment response, disease progression, and relapse.
14 A complete response (CR) included patients with a stringent CR (ie, having negative immunofixation results on serum and urine, the disappearance of any soft tissue plasmacytoma, <5% plasma cells in the bone marrow biopsy, and a normal free light chain ratio) 14 and patients with a near CR (ie, having only a positive immunofixation electrophoresis result). 16 
Statistical Methods
Summaries of patient demographics and clinical characteristics were produced for all patients and by MM group. Associations between MM group and categorical measures were assessed using either the Fisher exact test or a generalized Fisher exact test, whereas differences in continuous measures between groups were evaluated using the Wilcoxon rank-sum test. PFS was computed from the date of transplantation to the date of disease progression or death (if the patient died without disease progression) or the last evaluation date. Patients who remained alive and did not experience disease progression at the last follow-up date were censored. OS was computed from the date of transplantation to the last known vital sign. Patients who were alive at the last follow-up date were censored. The Kaplan-Meier method was used to estimate OS and PFS, and group differences were assessed using the log-rank test. The association between survival (OS and PFS) and patient subgroups was determined using Cox proportionalhazards regression models. Factors significantly associated with OS and PFS in univariate models (P < .05) were included in a multivariable model. The cumulative incidence of nonrelapse mortality (NRM) was determined using the competing-risks method. The competing risk for NRM included relapse; patients who were still alive at the last follow-up date were censored. Differences in NRM between groups were assessed using the Gray test. 17 All statistical analysis were performed using SAS 9.3 for Windows (SAS Institute Inc, Cary, NC). All statistical tests used a significant level of 5%. No adjustments were made for multiple testing.
RESULTS
Patient and Disease Characteristics
The study population consisted of 233 patients, including 105 (45%) with DR-MM and 128 (55%) with NDR-MM. Patient characteristics are summarized in Table 1 . The median age at auto-HCT was 59 years, and the patients with DR-MM were significantly older than those with NDR-MM (60 vs 56 years; P 5 .005). Compared with patients who had NDR-MM, those with DR-MM had higher rates of chemomobilization (51% vs 31%; P 5 .002), were more likely to be treated with a tripleregimen induction regimen (52% vs 21%; P < .001), and received more lines of therapy before transplantation (median, 2 lines vs 1 line; P < .001). In addition, patients 
Engraftment and NRM
The median number of infused CD34-positive cells was 4.8 3 10 6 cells/kg (with 4.7 3 10 6 in the DR-MM group and 4.8 3 10 6 in the NDR-MM group; P 5 .25). The median time to neutrophil engraftment was 11 days (range, 9-13 days) in the DR-MM group and 10 days (range, 0-19 days) in the NDR-MM group (P < .001). Similarly, the median time to platelet engraftment was 11 days (range, 0-34 days) and 10 days (range, 0-23 days), respectively (P 5 .016). The cumulative incidence of NRM was very low and was similar between the 2 groups (DR-MM group: day 100, 0%; month 6, 1%; NDR-MM group: day 100, 2%; month 6, 2%; P 5 .56). 
Treatment After and Response to Auto-HCT
Sixteen patients (7%) received consolidation therapy after transplantation, including 8 in the DR-MM group and 8 in the NDR-MM group (P 5 .80). Conversely, approximately one-half of patients (113 of 229) received maintenance therapy, and a significantly higher percentage of those in the DR-MM group (61%) received maintenance compared with the NDR-MM group (40%; P 5 .001). The distribution of maintenance regimens for all patients is presented in Table 1 . The most common maintenance regimen was lenalidomide. The ORR for all patients was 80% (188 of 233 patients; CR, 22%; very good PR, 18%; PR, 40%). Patients who had DR-MM had response rates similar to those who had NDR-MM (79% and 82%, respectively; P 5 .77).
Survival
The median follow-up after auto-HCT for surviving patients was 42 months (range, 6-192 months). Seventyfive percent of patients in the study experienced disease progression, and 60% died. The median PFS was 17.6 months, and the median OS was 48.0 months for all refractory patients (Figs. 1 and 2, respectively) . Although PFS and OS were longer for patients with NDR-MM (PFS, 18.2 months; OS, 56.6 months) than for those with DR-MM (PFS, 14.4 months; OS, 38.9 months), the differences were not statistically significant (P .27). In contrast, a significant association between PFS and type of refractory disease (relapsed and refractory vs primary refractory), hemoglobin level, cytogenetic risk, number of lines of prior chemotherapy, and prior disease status was noted. Patients with relapsed refractory MM (hazard ratio [HR], 1.9; P < .001), those with hemoglobin levels <10 g/dL (HR, 1.6; P 5 .004), patients with high-risk cytogenetic (HR, 2.2; P < .001), those who received more lines of prior treatment (HR, 1.2; P 5 .004), and those who had progressive disease before auto-HCT (HR, 2.1; P < .001) experienced worse outcomes. International Staging System scores did not have a significant impact on PFS at the .05 level. Taken together, only cytogenetic risk and the number of lines of prior chemotherapy remained independently associated with PFS.
Consistent with PFS, significant associations between OS and type of refractory disease, hemoglobin level, cytogenetic risk, number of lines of prior chemotherapy, and prior disease status were observed. Moreover, disease stage and induction treatment were significantly associated with OS. Patients who had relapsed and refractory MM (HR, 2.0; P < .001), hemoglobin levels < 10 g/ dL (HR, 1.8; P < .001), high-risk cytogenetics (HR, 2.3; P < .001), received more lines of prior treatment (HR, 1.2; P 5 .013), progressive disease before auto-HCT (HR, 2.4; P < .001), and received triplet-induction treatment (triplet vs doublet: HR, 1.6; P 5 .014) experienced an increased risk of death; whereas patients who were receiving maintenance treatment (HR, 0.7; P 5 .027) experienced a decreased risk of death. Number of lines of prior chemotherapy, prior disease status, and induction treatment were independent predictors of OS in the multivariable analysis.
DISCUSSION
Patients who have refractory myeloma present a unique treatment challenge in which clinical outcomes remain suboptimal despite the deployment of novel agents. The induction regimens using PIs and/or IMiDs are extremely effective and induce responses in >80% of patients; therefore, the patients who fail to respond or become refractory to these highly effective drugs represent a group with a particularly aggressive form of disease. The ideal treatment algorithm for these patients, who have a suboptimal response to induction therapy, is not clear. In the current report on our institutional experience in patients who have less than a PR before auto-HCT, we demonstrate that high-dose therapy (HDT) followed by auto-HCT is an effective therapy to induce response, even in patients who are refractory to novel agents.
In this study, the ORR for all patients was 80%, and 22% achieved a CR. In the NDR-MM cohort, 82% of patients achieved at least a PR or better, and 21% achieved a CR. Although most patients in the NDR-MM group were not exposed to a PI, 53% (n 5 68) did demonstrate refractoriness to an IMiD. In the DR-MM cohort, 79% achieved a least a PR, with 24% achieving a CR. These response rates are similar to rates reported in other studies evaluating patients with refractory disease who underwent auto-HCT, demonstrating the clear role and effectiveness of high-dose melphalan in this patient population. Combination therapy for patients with refractory myeloma with newer agents, including daratumumab, carfilzomib, elotuzumab, or panobinostat, have demonstrated ORRs of 60% to 90%, with 11% to 20% of patients achieving a CR. [18] [19] [20] [21] [22] Thus, auto-HCT yields impressive response rates with several CRs and will likely complement therapies using newer agents.
Despite the impressive response rates, the PFS and OS are lower than what would be expected in patients who have at least a PR. This correlates with results from other studies. Gertz et al evaluated patients based on their response to an IMiD before auto-HCT and observed that those who did not achieve a PR before auto-HCT had shorter PFS and OS (13.1 and 30.4 months, respectively) than those who demonstrated a response before transplantation (22.1 vs 73.5 months, respectively). 10 Similarly, Lee et al evaluated the impact of pretransplantation response to novel-based regimens (most were bortezomibbased) and observed that those who achieved less than a PR had a median PFS of 4.7 months and a median OS of 11.6 months, which were significantly lower than those who had a response before transplantation (patients with CRs and very good PRs had median PFS of 26.6 months, and median OS was not reached). 9 The outcomes in that study demonstrated poorer PFS and OS than those in the current study; however, there is no mention of using maintenance therapy in the former study, which may account at least in part for our improved outcomes.
Our DR-MM group had shorter PFS and OS compared with those in the NDR-MM group, although the difference was not statistically significant. However, it is important to point out that the groups were not matched, and there were important differences in patient characteristics. For instance, significantly more patients in the DR-MM group received induction with triplet regimens (52% vs 21% in the NDR-MM group; P < .001). Similarly, chemomobilization was used more often in the DR-MM group (51% vs 31% in the NDR-MM group; P 5 .002), and significantly more patients with DR-MM received maintenance therapy (61% vs 40% in the NDR-MM group; P 5 .001). It is also important to note that the majority of patients in the DR-MM group (65%) underwent auto-HCT after 2010, whereas the majority of patients in the NDR-MM group (74%) underwent transplantation before 2010. With US Food and Drug Administration approval of lenalidomide and thalidomide for MM in 2006 and of bortezomib for MM in 2008, many patients in the NDR-MM group did not have access to these agents and clearly represent a distinct population. Nevertheless, the median PFS of 14.4 months and the median OS of 38.9 months in patients who were refractory to both IMiDs and PIs is quite encouraging. For example, a large analysis of US patients from 2 independent databases by Usmani et al demonstrated that the median OS was only 6.7 months in double-refractory patients. 12 Overall, our data highlight that auto-HCT is an effective therapy for inducing response and possibly prolonging survival in patients with double-refractory disease. However, the role of auto-HCT in this scenario will continue to evolve as more effective IMiDs, PIs, and other agents become available. It is likely that these agents will augment the outcome of auto-HCT in these high-risk patients.
In our multivariable analysis, cytogenetic risk and the number of lines of prior chemotherapy were independently associated with PFS. Poorer outcomes in patients with high-risk cytogenetics have previously been described. 23, 24 Similarly, the current literature suggests that giving additional lines of therapy before auto-HCT to patients who do not respond to first-line therapy may not result in longer survival. For instance, a Center for International Blood and Marrow Research analysis indicated that further salvage therapy before auto-HCT in patients who do not achieve an optimal response to induction may improve the depth of response before auto-HCT but does not influence PFS or OS. 25 Consistent results were observed in a study of patients with primary refractory myeloma from the Mayo Clinic, in which the 3-year OS from the start of initial treatment was similar for those who proceeded to auto-HCT directly versus those who received additional chemotherapy. 8 The studies described above suggest that the patients who are eligible for transplantation may proceed to auto-HCT without further attempts to achieve a deeper response after failing initial induction therapy. However, this notion is likely going to be challenged in the future with the availability of newer and more potent antimyeloma agents.
Limitations to this study include its retrospective nature and nonstandardized induction and maintenance regimens, as well as reflecting old patterns of care (most patients in the NDR-MM group did not receive a PI before undergoing transplantation). There is also a possible selection bias of patients with nonresponsive disease who proceeded to transplantation, specifically in those who had relapsed/refractory disease. To attempt to capture the aggressiveness of the disease, we divided the relapsed/refractory subgroup into 2 groups based on whether they progressed within 6 months of initial response versus 6 months after initial response. No significant difference was observed in OS or PFS between these groups. Noting that the treatment paradigms and supportive care guidelines have changed over the course of time in our cohort of patients, we evaluated the year of transplantation with respect to transplantation outcomes. There was no statistically significant difference in the year of transplantation for OS or PFS in the univariable or multivariable model.
The strengths of this study include its large sample size, in which we demonstrated the effectiveness of HDT and auto-HCT in this difficult patient population, with the majority of patients able to achieve a response and a proportion of those able to achieve a CR. Considering the current treatment options, combined HDT with auto-HCT stands as an effective tool to implement response in patients who have refractory myeloma; however, further studies should be performed to evaluate the role of auto-HCT in combination with newer agents.
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